The chairman of Swiss drugmaker Novartis (NOVN.S) expects Alcon to be valued at between $20 billion (15.14 billion pounds) and $30 billion when the opthalmic devices unit is spun off to shareholders next year, he said in an interview with Finanz und Wirtschaft.
Copyright © 2018,